Skip to main content
. 2018 Apr 5;38(7):1493–1503. doi: 10.1161/ATVBAHA.118.311212

Figure 5.

Figure 5.

Inhibition of ATP citrate lyase (ACLY) results in the increase in Abcg5/8 (ATP-binding cassette transporter G5/G8) expression accompanying a reduction of period 2 (PER2) at Abcg5/8 promoter in primary hepatocytes. A, Real-time quantitative polymerase chain reaction (qPCR) analysis of Abcg5, Abcg8, and Bsep in primary hepatocytes treated with ACLY inhibitor, BMS 303141 (8 μmol/L), for 20 hours (n=3). B, Chromatin immunoprecipitation (ChIP) assay using endogenous Per2 antibody at the Abcg5/8 promoter or (C) Dbp promoter in primary hepatocytes treated with DMSO or iACLY (n=3–4 pooled). D, Real-time qPCR analysis of Abcg5 and Abcg8 in primary hepatocytes from Prkaa1 wild-type (WT) and Prkaa1 knockout (KO) animals treated with ACLY inhibitor, BMS 303141 (8 μmol/L) for 20 hours (n=3). E, Western blot of phosphorylation of ACC1 (acetyl-CoA carboxylase 1) at Ser 79 in cells treated with iACLY (8 μmol/L) or metformin (0.5 mmol/L) for 20 hours. Data represents mean±SD. *P<0.05, **P<0.01 using unpaired Student t test. B and C, Data represents mean±SD using ordinary 2-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (D).